Insider Transactions in Q1 2021 at Vanda Pharmaceuticals Inc. (VNDA)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Aranthan Jones Ii Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
18,000
-16.08%
|
$306,000
$17.72 P/Share
|
|
Mar 15
2021
|
Aranthan Jones Ii Chief Corp. Affairs Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+11.82%
|
$165,000
$11.32 P/Share
|
|
Mar 08
2021
|
Mihael Hristos Polymeropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
175,000
-12.54%
|
$3,150,000
$18.0 P/Share
|
|
Mar 05
2021
|
Timothy Williams SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,600
-3.03%
|
$95,200
$17.87 P/Share
|
|
Mar 02
2021
|
Aranthan Jones Ii Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
3,865
-3.83%
|
$69,570
$18.04 P/Share
|
|
Mar 02
2021
|
Joakim Wijkstrom SVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
3,888
-4.74%
|
$69,984
$18.45 P/Share
|
|
Mar 02
2021
|
Gunther Birznieks SVP, Business Development |
SELL
Open market or private sale
|
Direct |
16,620
-8.83%
|
$299,160
$18.19 P/Share
|
|
Mar 02
2021
|
Kevin Patrick Moran SVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
6,044
-5.62%
|
$108,792
$18.23 P/Share
|
|
Mar 02
2021
|
Mihael Hristos Polymeropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
15,206
-1.08%
|
$273,708
$18.34 P/Share
|
|
Mar 02
2021
|
Timothy Williams SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
7,674
-7.66%
|
$138,132
$18.54 P/Share
|
|
Mar 01
2021
|
Gunther Birznieks SVP, Business Development |
SELL
Open market or private sale
|
Direct |
3,845
-2.0%
|
$69,210
$18.66 P/Share
|
|
Mar 01
2021
|
Kevin Patrick Moran SVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
3,327
-3.0%
|
$59,886
$18.57 P/Share
|
|
Mar 01
2021
|
Mihael Hristos Polymeropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
7,479
-0.53%
|
$134,622
$18.45 P/Share
|
|
Mar 01
2021
|
Timothy Williams SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
11,856
-10.58%
|
$213,408
$18.6 P/Share
|
|
Feb 24
2021
|
Gunther Birznieks SVP, Business Development |
BUY
Grant, award, or other acquisition
|
Direct |
32,700
+14.54%
|
-
|
|
Feb 24
2021
|
Aranthan Jones Ii Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
22,986
-18.57%
|
$459,720
$20.01 P/Share
|
|
Feb 24
2021
|
Aranthan Jones Ii Chief Corp. Affairs Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,499
+15.38%
|
$269,988
$12.27 P/Share
|
|
Feb 24
2021
|
Aranthan Jones Ii Chief Corp. Affairs Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,800
+20.3%
|
-
|
|
Feb 24
2021
|
Kevin Patrick Moran SVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
32,700
+22.79%
|
-
|
|
Feb 24
2021
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+7.5%
|
-
|
|
Feb 24
2021
|
Joakim Wijkstrom SVP, Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,800
+23.91%
|
-
|
|
Feb 24
2021
|
Timothy Williams SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
32,700
+22.59%
|
-
|
|
Feb 16
2021
|
Richard W Dugan |
SELL
Open market or private sale
|
Direct |
5,754
-9.49%
|
$103,572
$18.54 P/Share
|
|
Feb 16
2021
|
Richard W Dugan |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+19.83%
|
$105,000
$7.11 P/Share
|
|
Feb 16
2021
|
Thomas Watkins Director |
SELL
Open market or private sale
|
Direct |
5,818
-10.52%
|
$104,724
$18.54 P/Share
|
|
Feb 16
2021
|
Thomas Watkins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+21.33%
|
$105,000
$7.11 P/Share
|